US Patent 9,532,944: Scope, Claims, Expiration, and Varenicline Patent Landscape

US Patent 9,532,944 protects methods of treating ocular discomfort by administering varenicline into the nasal cavity at a low, locally acting dose. The patent is directed to a mechanism in which nasal nicotinic acetylcholine receptor activation stimulates trigeminal and nasolacrimal pathways that increase basal tear production. Its commercial relevance is tied primarily to Tyrvaya, the varenicline nasal spray marketed by Viatris.

The core claim requires all of the following: ocular discomfort, nasal administration, varenicline, selective peripheral nicotinic acetylcholine receptor binding, a 5-to-50-microgram non-systemically bioavailable dose, and no pharmacologically relevant blood-brain-barrier penetration. The patent’s nominal expiration date is June 21, 2030, subject to any applicable patent-term adjustment and regulatory listing changes.[1][2]

What does US Patent 9,532,944 protect?

The patent protects a method of treating ocular discomfort through nasal delivery of a peripheral nicotinic acetylcholine receptor agonist, specifically varenicline.

Claim element	Scope
Disease or condition	Ocular discomfort
Route	Local administration into the nasal cavity
Active ingredient	Varenicline
Pharmacology	Selective binding to peripheral nicotinic acetylcholine receptors
Dose	5 to 50 micrograms per dose
Distribution	Non-systemically bioavailable
CNS limitation	Does not cross the blood-brain barrier at a pharmacologically relevant concentration
Claimed effect	Improvement of ocular discomfort
Additional mechanisms	Trigeminal nerve activation and nasolacrimal reflex activation

Claim 1 is the independent method claim. Claims 2 through 15 narrow the method by adding receptor subtypes, safety limitations, dosing frequency, formulations, devices, and proposed neural mechanisms.

The claim is narrower than a broad claim covering any nasal varenicline product. A potentially infringing product must satisfy the therapeutic-use, route, dose, pharmacology, and distribution limitations. A product that delivers varenicline nasally for a non-ocular indication would not necessarily fall within claim 1.

How does claim 1 define the patent’s commercial scope?

Claim 1 is the principal commercial claim because it covers the basic clinical use of low-dose nasal varenicline for ocular discomfort.

The claim has five important limitations.

Ocular discomfort must be treated

The method requires administration to an individual in need of treatment for ocular discomfort. This language can cover dry-eye symptoms and related discomfort, but it does not expressly limit the indication to a particular diagnostic classification such as aqueous-deficient dry-eye disease.

The scope may include symptoms such as burning, irritation, foreign-body sensation, or ocular dryness if the treatment is directed to ocular discomfort. Whether a particular use falls within the claim depends on the product labeling, prescribing context, and evidence concerning the intended therapeutic use.

Administration must occur in the nasal cavity

The claim does not cover topical ocular administration of varenicline. It requires delivery into the nasal cavity.

This limitation distinguishes the patent from conventional ophthalmic drops, gels, inserts, and contact-lens delivery systems. It also creates potential design-around opportunities involving systemic administration or direct ocular delivery, although those approaches would need to be evaluated against other patents and regulatory requirements.

The dose must be between 5 and 50 micrograms per dose

The dose range is a central limitation. Tyrvaya delivers 0.03 mg, or 30 micrograms, per spray. The approved regimen is one spray in each nostril twice daily.[3]

The interpretation of “per dose” matters. If “dose” means each spray or each nostril, the marketed 30-microgram spray falls within the claimed range. If “dose” means the aggregate amount delivered during a two-nostril administration, the total is 60 micrograms and exceeds the literal 5-to-50-microgram range. Patent litigation would likely examine the technical meaning of dose in the specification, prosecution history, and product administration instructions.

The drug must act peripherally and avoid pharmacologically relevant CNS exposure

The claim requires that varenicline selectively bind to peripheral nicotinic acetylcholine receptors and not cross the blood-brain barrier at a pharmacologically relevant concentration.

This limitation is important because varenicline is also known as a centrally active nicotinic receptor ligand when administered systemically for smoking cessation. The patent distinguishes the claimed nasal ocular-use regimen from systemic exposure associated with central nervous system effects.

The relevant inquiry is not whether any molecule reaches the brain. The claim uses a pharmacological threshold: the concentration must not be relevant to pharmacological activity. Product pharmacokinetics, exposure studies, formulation data, and expert testimony would likely determine whether this limitation is met.

Varenicline is expressly required

Although the claim begins with a broader class of nicotinic acetylcholine receptor agonists, it ends by specifying that the agonist is varenicline. The claim therefore does not remain open to all agonists at the point of final limitation.

A competing product containing another nicotinic agonist could avoid literal infringement of claim 1. It could still present risk under other patent claims if a continuation or related patent covers the broader agonist class, a formulation, a device, or a different treatment method.

What do claims 2 through 15 add?

The dependent claims create narrower positions that may be useful in enforcement but generally provide less commercial breadth than claim 1.

Claims	Added limitation	Practical significance
2	Alpha3beta4, alpha4beta2, or alpha7 receptor subtype	Narrows the pharmacological profile
3	No undesired psychoactive side effects	Introduces a clinical and evidentiary limitation
4	No undesired systemic side effects	Requires evaluation of systemic tolerability
5	Co-administration of a substance affecting receptor desensitization	Covers combination approaches
6	PKC, PKA, modulators, or calcineurin inhibitors	Defines specific desensitization-control mechanisms
7	Cyclosporine, pimecrolimus, or tacrolimus	Covers selected calcineurin inhibitors
8	At least once daily	Covers daily dosing
9	At least twice daily	Closely corresponds to the Tyrvaya regimen
10	At least once weekly	Broadens the frequency interval
11	Liquid, suspension, aerosol, gel, ointment, dry powder, and other dosage forms	Covers multiple nasal dosage forms
12	Syringe, dropper, nebulizer, atomization pump, inhaler, and other devices	Covers delivery hardware
13	Trigeminal nerve activation	Adds a proposed mechanism
14	Anterior ethmoidal nerve activation	Adds a more specific neural pathway
15	Nasolacrimal reflex activation	Adds the proposed tear-stimulation mechanism

Claims 11 and 12 are particularly relevant to product-development analysis. A nasal varenicline product using a different formulation or device may still fall within these claims if it satisfies the other limitations of claim 1.

Claims 13 through 15 are more vulnerable to proof issues because they require a physiological mechanism that may not be directly observable from ordinary product use. They may be useful as fallback claims if the mechanism is established by pharmacology or clinical evidence.

What is the FDA status of the drug covered by the patent?

Tyrvaya is FDA-approved varenicline solution nasal spray for the treatment of the signs and symptoms of dry eye disease. The FDA approved New Drug Application 214826 on October 15, 2021.[3][4]

Regulatory item	Information
Product	Tyrvaya
Active ingredient	Varenicline tartrate
Dosage form	Nasal spray
Strength	0.03 mg varenicline per spray
Administration	One spray in each nostril twice daily
Applicant at approval	Oyster Point Pharma
Current commercial owner	Viatris, following its acquisition of Oyster Point
NDA	214826
FDA approval date	October 15, 2021
Therapeutic area	Dry eye disease

The approved product’s nasal route, 30-microgram spray strength, twice-daily regimen, and tear-production mechanism align closely with the subject patent’s method claims.

What is the Orange Book status of US Patent 9,532,944?

US Patent 9,532,944 has been listed in the FDA Orange Book for Tyrvaya. The listed patent expiration date is June 21, 2030.[2]

The patent is a use patent rather than a patent directed solely to the chemical structure of varenicline. That distinction affects generic approval strategy. An ANDA applicant may seek approval with a Paragraph IV certification asserting that the listed patent is invalid, unenforceable, or not infringed. A generic applicant may also attempt a section viii statement carving out a patented method of use if the proposed label can omit the protected indication. For a product whose commercial purpose is treatment of dry eye disease, a section viii strategy would be difficult if the patented use is the principal or only approved use.

The patent does not create new chemical entity exclusivity for varenicline. Varenicline was previously approved for smoking cessation. Any FDA exclusivity associated with the dry-eye approval would therefore be separate from NCE exclusivity and would depend on the applicable clinical-investigation exclusivity determination.[3][4]

When does US Patent 9,532,944 lose exclusivity?

The nominal patent expiration date is June 21, 2030.

Event	Date or status
Earliest relevant priority date	June 21, 2010
Patent issue date	December 27, 2016
Nominal expiration	June 21, 2030
FDA approval of Tyrvaya	October 15, 2021
Likely first ANDA approval timing absent litigation delay	After applicable regulatory exclusivity and patent barriers
Pediatric extension	No extension is identified in the cited materials

The effective generic-entry date may be earlier than June 21, 2030 if a challenger prevails in litigation, reaches a settlement with the patent owner, or obtains approval through a label strategy that avoids the patented use.

Which companies own or commercialize the relevant rights?

Oyster Point Pharma developed Tyrvaya and held the commercial program at FDA approval. Viatris acquired Oyster Point Pharma in 2023 and became the principal commercial owner of the product and related assets.[5]

The transaction was an acquisition rather than a simple field-of-use license. Publicly available information identifies Viatris as the relevant commercial patent and product stakeholder following the transaction.

There is no basis in the supplied materials to identify a separate licensee with independent rights to US Patent 9,532,944.

Which companies are challenging the Tyrvaya patent?

The supplied claim set does not identify an ANDA challenger, Paragraph IV notice, district-court complaint, or settlement agreement.

Accordingly, no specific challenger can be attributed to US Patent 9,532,944 solely from the patent claims. A definitive challenger analysis requires the FDA Paragraph IV records, Orange Book updates, ANDA litigation filings, and any confidential or subsequently disclosed settlement terms.

The principal litigation risk would arise from a generic varenicline nasal spray seeking approval for dry eye disease. The likely dispute points would include:

Whether the generic delivers 5 to 50 micrograms per dose.
Whether the formulation is non-systemically bioavailable.
Whether varenicline acts selectively at peripheral receptors in the claimed clinical context.
Whether the proposed label induces use for ocular discomfort.
Whether the nasal spray activates the claimed tear-production pathway.
Whether the patent claims are enabled and adequately supported across the full claim scope.

How strong is the patent estate?

US Patent 9,532,944 has meaningful commercial strength because it aligns closely with the approved Tyrvaya product. Its strongest features are the combination of varenicline, nasal administration, the low-dose range, and treatment of ocular discomfort.

Its principal vulnerabilities are claim construction and proof of functional limitations.

Strength	Risk
Covers the approved route and indication	“Ocular discomfort” may require interpretation
Dose range overlaps the marketed spray	“Per dose” may create a dosing dispute
Varenicline is expressly recited	Peripheral selectivity may be contested
FDA-approved product supports enablement arguments	BBB and systemic-bioavailability limitations may require pharmacokinetic evidence
Twice-daily dosing is expressly claimed	Dependent claims add narrower limitations
Nasal delivery devices and formulations are covered	Alternative devices or doses may support design-around arguments

The patent is stronger against a generic that copies the approved strength, route, indication, and twice-daily regimen. It is less complete as a standalone barrier against products using different doses, different agonists, different indications, or non-nasal delivery.

What generic launch scenarios exist?

Three scenarios are commercially plausible.

Launch after patent expiration

A generic may wait until the nominal June 2030 expiration date. This avoids litigation risk but delays market entry.

Paragraph IV challenge

A generic may certify that the patent is invalid, unenforceable, or not infringed. The patent owner could sue within 45 days, potentially triggering a statutory 30-month stay of approval under the Hatch-Waxman framework.[6]

The most likely defenses would focus on obviousness, written description, enablement, dose interpretation, peripheral selectivity, and lack of infringement.

Label carve-out

A generic may seek approval without the patented dry-eye indication if the proposed labeling can omit the protected use. This approach is commercially weak if the dry-eye indication is the product’s only meaningful market and if the labeling or promotional environment would still encourage the patented use.

What geographic coverage does the patent provide?

US Patent 9,532,944 provides rights only in the United States. Foreign counterparts, national-phase patents, continuations, and divisional applications must be analyzed separately.

US patent coverage does not block manufacture or sale outside the United States unless separate foreign rights exist. It can, however, affect importation into the United States, US commercial supply, contract manufacturing, and distribution of a nasal varenicline product.

Manufacturing know-how may create an additional barrier, but the patent claims supplied here are primarily method claims. They do not independently establish protection for a specific manufacturing process, container-closure system, or device design.

Key Takeaways

US Patent 9,532,944 protects nasal administration of low-dose varenicline for improving ocular discomfort.
The core claim requires a 5-to-50-microgram dose, peripheral nicotinic receptor activity, limited systemic availability, and no pharmacologically relevant BBB penetration.
Tyrvaya’s 30-microgram-per-spray, twice-daily nasal regimen closely tracks the claimed subject matter.
The patent’s nominal expiration date is June 21, 2030.
Tyrvaya was FDA-approved on October 15, 2021, under NDA 214826.
Viatris became the principal commercial owner after acquiring Oyster Point Pharma.
The main infringement risks concern dose interpretation, peripheral activity, pharmacokinetics, and label-induced use.
The supplied materials do not identify a specific Paragraph IV challenger or settlement.
Alternative agonists, doses, routes, and indications may offer design-around paths, but related continuation and formulation patents must also be reviewed.

FAQs About US Patent 9,532,944

Does US Patent 9,532,944 cover all varenicline products?

No. It covers a defined method involving nasal administration for ocular discomfort. Oral varenicline products for smoking cessation fall outside the claim unless they satisfy every limitation.

Does Tyrvaya infringe the 5-to-50-microgram limitation?

Tyrvaya delivers 30 micrograms per spray, which falls within the stated range when measured per spray or nostril. The legal outcome can depend on how “per dose” is construed.

Can a generic use a different nasal spray device?

Possibly. A different device does not automatically avoid infringement because claim 1 is not limited to a particular device. Claims 11 and 12 separately address formulations and delivery devices.

Would a different nicotinic receptor agonist avoid the patent?

It may avoid literal infringement of claim 1 because the claim expressly requires varenicline. Other patents in the family or related patent estate could still cover alternative agonists.

Is the patent a composition-of-matter patent for varenicline?

No. The supplied claims are method claims. They protect a therapeutic use and administration approach rather than the underlying varenicline molecule.

References

United States Patent and Trademark Office. (2016). US Patent No. 9,532,944, Methods of treating ocular discomfort using nicotinic acetylcholine receptor agonists.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2021). Tyrvaya prescribing information.
U.S. Food and Drug Administration. (2021). Approval letter for NDA 214826, Tyrvaya.
Viatris Inc. (2023). Viatris completes acquisition of Oyster Point Pharma and Famy Care.
21 U.S.C. § 355(j). Abbreviated applications for new drugs and patent certifications.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015336216	⤷ Start Trial
Australia	2020213351	⤷ Start Trial
Brazil	112017008097	⤷ Start Trial
Brazil	122022025737	⤷ Start Trial
Canada	2965129	⤷ Start Trial
China	107106542	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,532,944

Which drugs does patent 9,532,944 protect, and when does it expire?

Summary for Patent: 9,532,944